Evaluation of Candidates for Promotion Sample Clauses

Evaluation of Candidates for Promotion. Each Department Head shall evaluate the teaching, research, and professional service of each Faculty Member who is in that year a candidate for promotion.
AutoNDA by SimpleDocs
Evaluation of Candidates for Promotion. The staff’s past performance and his/her potential to perform at the clinical level being pursued determines eligibility for promotion. Advancement within the ladder is available to all RNs provided they meet the Clinical Ladder criteria. Once in a level, RN must function in that role for a period of no less than one year before applying for a promotion to the next level. Application Process: Initial Advancement to the Next Level Only (suggested time line from the initial application submission to the final decision is 6-8 weeks). If approved, advancement payment will be retroactive up to 30 days from the initial application submission:

Related to Evaluation of Candidates for Promotion

  • Selection of Candidates 5.12 The Appointments Committee shall consider all candidates for a Probationary, Tenured, Limited-Term, Externally-Funded or Visiting position and shall interview all short-listed candidates who present themselves for interview.

  • Criteria for Promotion 24.04.01 For evaluating each application for promotion, the following general criteria shall apply:

  • Eligibility for Promotion An employee in the classification of Police Officer must have a minimum of five (5) years service in the classification of Lincoln Police Officer as of March 1 of the testing year to be eligible to test for the classification of Sergeant.

  • Application for Promotion Employees who have successfully completed their initial probationary period may make application for any Job Posting provided they meet the minimum, stated qualifications for the involved position; provided, however, that employees who have failed a promotional probationary period in a classification shall not be permitted to take an examination for promotion to that classification within twelve (12) months of the date of such failure.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Rates for Unbranding and Custom Branding via OLNS software for Directory Assistance and for Operator Call Processing are as set forth in Exhibit E of this Attachment. Notwithstanding anything to the contrary in this Agreement, to the extent BellSouth is unable to xxxx Comm South applicable charges currently, BellSouth shall track such charges and will xxxx the same retroactively at such time as a billing process is implemented. In addition to the charges for Unbranding and Custom Branding via OLNS software, Comm South shall continue to pay BellSouth applicable labor and other charges for the use of BellSouth's Directory Assistance and Operator Call Processing platforms as set forth in Exhibit E of this Attachment.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Orally Administered Anticancer Medication In accordance with RIGL § 27-20-67, prescription drug coverage for orally administered anticancer medications is provided at a level no less favorable than coverage for intravenously administered or injected cancer medications covered under your medical benefit.

  • Candidates The Superintendent or designee shall invite all current candidates for the office of Board member to attend: (1) Board meetings, except that this invitation shall not extend to any closed meetings, and (2) pre-election workshops for candidates. LEGAL REF.:5 ILCS 120/1.05 and 120/2. 105 ILCS 5/10-16a and 5/24-16.5. CROSS REF.:2:80 (Board Member Oath and Conduct), 2:125 (Board Member Compensation; Expenses), 2:200 (Types of Board of Education Meetings) ADOPTED:February 21, 2017 Urbana S.D. 116 2:120-E1 Exhibit - Guidelines for Serving as a Mentor to a New Board of Education Member On District letterhead Date Dear Board of Education Member: Thank you for agreeing to serve as a mentor to a new Board member. The goal of the mentoring program is to orient a new Board member to the Board and District and to help him or her be comfortable, develop self-confidence, and become an effective leader. Follow these guidelines to maximize your mentoring effectiveness.

Time is Money Join Law Insider Premium to draft better contracts faster.